Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
36.92
+0.69 (1.90%)
At close: Jan 21, 2026, 4:00 PM EST
36.53
-0.39 (-1.06%)
After-hours: Jan 21, 2026, 7:31 PM EST
Nektar Therapeutics Employees
Nektar Therapeutics had 61 employees as of December 31, 2024. The number of employees decreased by 76 or -55.47% compared to the previous year.
Employees
61
Change (1Y)
-76
Growth (1Y)
-55.47%
Revenue / Employee
$1,026,230
Profits / Employee
-$1,979,279
Market Cap
751.01M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 61 | -76 | -55.47% |
| Dec 31, 2023 | 137 | -79 | -36.57% |
| Dec 31, 2022 | 216 | -524 | -70.81% |
| Dec 31, 2021 | 740 | 22 | 3.06% |
| Dec 31, 2020 | 718 | -5 | -0.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 837 |
| Gyre Therapeutics | 579 |
| REGENXBIO | 353 |
| Prime Medicine | 214 |
| Kura Oncology | 192 |
| Astria Therapeutics | 78 |
| Arbutus Biopharma | 44 |
| Jade Biosciences | 30 |
NKTR News
- 6 days ago - Nektar.io Introduces DIRT: Materials Management for the Construction Industry - Newsfile Corp
- 5 weeks ago - Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg - Seeking Alpha
- 5 weeks ago - Nektar Therapeutics (NKTR) Discusses Topline Results From REZOLVE-AA Phase 2b Study of rezpegaldesleukin in Alopecia Areata Transcript - Seeking Alpha
- 5 weeks ago - Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion - Benzinga
- 5 weeks ago - Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 - PRNewsWire
- 6 weeks ago - Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 2 months ago - Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets - Seeking Alpha
- 2 months ago - Nektar Therapeutics: Cautiously Positive Moving Into Phase 2b Readout - Seeking Alpha